Zhejiang Tianyu Pharmaceutical Co., Ltd.
SZSE:300702.SZ
20.8 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2,630.808 | 2,527.27 | 2,666.678 | 2,545.01 | 2,587.396 | 2,110.596 | 1,466.956 | 1,188.283 | 1,082.339 | 840.085 | 777.35 | 723.25 |
| Cost of Revenue
| 1,719.081 | 1,537.222 | 1,979.137 | 1,612.2 | 1,251.009 | 926.402 | 876.268 | 739.07 | 676.998 | 563.539 | 556.778 | 522.335 |
| Gross Profit
| 911.728 | 990.048 | 687.542 | 932.81 | 1,336.387 | 1,184.194 | 590.688 | 449.213 | 405.34 | 276.546 | 220.571 | 200.915 |
| Gross Profit Ratio
| 0.347 | 0.392 | 0.258 | 0.367 | 0.516 | 0.561 | 0.403 | 0.378 | 0.375 | 0.329 | 0.284 | 0.278 |
| Reseach & Development Expenses
| 238.898 | 243.822 | 231.104 | 227.4 | 179.065 | 112.255 | 79.46 | 59.21 | 58.73 | 41.408 | 31.076 | 32.743 |
| General & Administrative Expenses
| 100.61 | 95.458 | 126.512 | 139.849 | 105.077 | 115.768 | 93.487 | 71.03 | 55.805 | 47.969 | 36.525 | 133.909 |
| Selling & Marketing Expenses
| 85.863 | 83.293 | 47.426 | 32.203 | 33.345 | 43.541 | 37.475 | 27.047 | 25.534 | 23.428 | 22.004 | 17.785 |
| SG&A
| 186.473 | 178.751 | 173.939 | 172.052 | 138.422 | 159.309 | 130.962 | 98.077 | 81.339 | 71.397 | 58.529 | 151.694 |
| Other Expenses
| 401.483 | 496.727 | -8.67 | -21.671 | -6.869 | 7.788 | -23.179 | -1.193 | 8.227 | 4.686 | -0.411 | 18.963 |
| Operating Expenses
| 826.855 | 919.301 | 647.119 | 697.124 | 579.854 | 476.972 | 361.811 | 276.397 | 253.973 | 208.094 | 167.376 | 157.769 |
| Operating Income
| 84.873 | 145.837 | -101.834 | 240.08 | 775.745 | 688.313 | 195.754 | 119.888 | 137.787 | 55.947 | 26.55 | 20.347 |
| Operating Income Ratio
| 0.032 | 0.058 | -0.038 | 0.094 | 0.3 | 0.326 | 0.133 | 0.101 | 0.127 | 0.067 | 0.034 | 0.028 |
| Total Other Income Expenses Net
| -6.235 | -68.703 | -30.834 | -21.671 | -6.869 | -4.21 | -26.233 | -37.606 | 5.534 | 4.048 | -22.392 | 18.709 |
| Income Before Tax
| 78.638 | 77.134 | -110.504 | 218.409 | 768.876 | 684.102 | 189.304 | 118.696 | 143.321 | 59.994 | 26.656 | 39.057 |
| Income Before Tax Ratio
| 0.03 | 0.031 | -0.041 | 0.086 | 0.297 | 0.324 | 0.129 | 0.1 | 0.132 | 0.071 | 0.034 | 0.054 |
| Income Tax Expense
| 22.703 | 44.558 | 8.449 | 13.733 | 101.815 | 98.376 | 25.642 | 18.514 | 20.983 | 9.64 | 2.516 | 5.468 |
| Net Income
| 55.935 | 27.359 | -118.953 | 204.676 | 667.061 | 585.726 | 163.662 | 100.182 | 122.338 | 50.355 | 24.14 | 33.588 |
| Net Income Ratio
| 0.021 | 0.011 | -0.045 | 0.08 | 0.258 | 0.278 | 0.112 | 0.084 | 0.113 | 0.06 | 0.031 | 0.046 |
| EPS
| 0.16 | 0.08 | -0.34 | 0.59 | 2.06 | 1.8 | 0.51 | 0.38 | 0.51 | 0.21 | 0.1 | 0.14 |
| EPS Diluted
| 0.16 | 0.08 | -0.34 | 0.59 | 2.05 | 1.79 | 0.51 | 0.38 | 0.51 | 0.21 | 0.1 | 0.14 |
| EBITDA
| 466.532 | 426.952 | 187.136 | 431.995 | 911.458 | 801.654 | 291.474 | 221.469 | 179.416 | 95.354 | 89.871 | 43.147 |
| EBITDA Ratio
| 0.177 | 0.169 | 0.07 | 0.17 | 0.352 | 0.38 | 0.199 | 0.186 | 0.166 | 0.114 | 0.116 | 0.06 |